Alkermes plc (NASDAQ:ALKS), a leading global biopharmaceutical company based in Ireland, is making significant strides in the development of treatments for neurological and psychiatric disorders. With a focus on conditions such as alcohol and opioid dependence, schizophrenia, and bipolar I disorder, Alkermes is also exploring new territories with its pipeline targeting narcolepsy and idiopathic hypersomnia. The company's presence is bolstered by its corporate office and R&D center in Massachusetts, alongsid ...